Real-World Progression-Free Survival with Erlotinib versus Osimertinib in EGFR L858R+T790M Compound Mutation Non-Small Cell Lung Cancer: An Exploratory Analysis of the MSK-CHORD Dataset
Zeinab Dalloul, Ahmad Abboud, Iman Dalloul, Mahmoud Abdelsalam
This paper analyzes real-world progression-free survival in EGFR L858R+T790M compound mutation NSCLC patients treated with erlotinib or osimertinib, finding no osimertinib advantage and a significant cross-cohort interaction.
bioRxiv · Jun 30, 2026 · PreprintBioinformatics